# A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

> **NCT01399697** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 261 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** methotrexate
- **DRUG:** methotrexate
- **DRUG:** placebo
- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT01399697
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2015-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01399697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01399697, "A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01399697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*